Colgate-Palmolive remains a Buy, supported by resilient fundamentals, an attractive and still sustainable dividend yield while they hold the Dividend King status, and prudent valuation amid macro and geopolitical headwinds. CL posted solid Q1 results, with 8.4% net sales growth, robust free cash flow, and reaffirmed 2026 sales and EPS growth guidance despite Iran-driven margin pressures. Rising input and logistics costs, driven by the Iran conflict, are expected to pressure gross margins, but CL's strong cash flows support ongoing shareholder returns.
CL beats Q1 earnings estimates as pricing and volume lift sales 8.4%; costs and SGPP charges weigh on margins, but outlook stays intact.
Colgate-Palmolive Company (CL) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Colgate-Palmolive (CL) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Colgate-Palmolive (CL) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.91 per share a year ago.
The maker of consumer products, including toothpaste, deodorant and soap, posted net income of $646 million, or 80 cents a share, down from $690 million, or 85 cents a share, the year prior.
PG's innovation-led strategy drives growth, with strong product launches, brand gains and supply chain upgrades reinforcing long-term competitive advantage.
The consumer goods giants that built empires on household staples are struggling to justify their valuations. At the time of writing, Nestlé has shed nearly a quarter of its market value over the past five years.
CL eyes Q1 growth with rising sales and EPS, but cost pressures and weak volumes may limit upside despite innovation and premium push.
Caprock Group LLC raised its stake in Colgate-Palmolive Company (NYSE: CL) by 116.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 64,808 shares of the company's stock after acquiring an additional 34,879 shares during the period. Caprock Group LLC's
Boston Trust Walden Corp grew its holdings in shares of Colgate-Palmolive Company (NYSE: CL) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 170,118 shares of the company's stock after purchasing an additional 7,434 shares during the quarter.
Cwm LLC grew its position in shares of Colgate-Palmolive Company (NYSE: CL) by 20.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,345 shares of the company's stock after purchasing an additional 7,665 shares during the quarter. Cwm LLC's holdings in